Novo Nordisk A/S

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

Novo Nordisk A/S (NYSE: NVO) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. 

Kalkine’s Dividend Income Report covers the Company Overview, Key positives & negatives, Investment summary, Key investment metrics, Top 10 shareholding, Business updates and insights into company recent financial results, Key Risks & Outlook, Price performance and technical summary, Target Price, and Recommendation on the stock.

Price Performance:

• Trend Structure and Moving Averages: NVO remains in a downward trend, trading below its 21-day and 50-day moving averages, though recent stabilization around USD 46–47 suggests the stock may be forming a short-term base near its yearly low.
• Momentum Indicators: The RSI near 40 reflects weak but steadying momentum, with subtle higher lows hinting at early signs of improving internal strength despite the lack of a confirmed reversal signal.
• Volume and Technical Outlook: Volume remains moderate, with reduced selling pressure in recent sessions; however, a sustained break above the 21-day and 50-day averages is needed to signal a meaningful recovery from current levels.

1.2 The Key Positives, Negatives, and Investment summary   

1.3 Top 10 shareholders:

The top 10 shareholders together form ~3.23% of the total shareholding, signifying diverse shareholding. Capital International Investors and Loomis, Sayles & Company, L.P. are the biggest shareholders, holding the maximum stake in the company at ~0.53% and ~0.48%, respectively.

1.4 Dividend payments with impressive dividend yield:

Novo Nordisk (NVO), with a dividend yield of 3.69%, has maintained a consistent and shareholder-friendly dividend record, demonstrated by a long history of annual increases supported by strong cash generation from its diabetes and obesity franchises. The company follows a progressive dividend policy, aiming to raise the dividend over time in line with sustainable earnings growth while retaining flexibility to fund acquisitions, R&D expansion, and large-scale capacity investments. Dividend payouts have historically grown at a steady pace, reflecting management’s confidence in long-term profitability; however, the recent sharp share price correction has elevated the nominal yield above historical averages. While NVO continues returning substantial capital through both dividends and share buybacks, its dividend decisions remain closely tied to operating performance, restructuring impacts, and strategic reinvestment needs tied to its high-growth GLP-1 pipeline.

1.5 Key Metrics

Novo Nordisk’s Q2FY25 profitability metrics significantly outperform industry medians across every major measure, underscoring the company’s exceptional operating efficiency and pricing power driven by its GLP-1 diabetes and obesity portfolio. Gross margin of 83.3% vs. the industry’s 74.1% highlights NVO’s advantaged cost structure and premium product mix, while its EBITDA (49.8%) and operating margins (43.5%) far exceed sector norms, reflecting disciplined cost control and strong scalability despite ongoing restructuring expenses. Pretax and net margins of 44.0% and 34.5%, roughly double industry medians, reinforce the company’s superior profitability engine even as competition intensifies. Notably, NVO’s effective tax rate aligns exactly with the industry median (21.6%), indicating that margin outperformance stems from core operations rather than tax advantages, collectively positioning NVO as one of the most financially robust players in global biopharma.

Section 2: Business Updates and Financial Highlights

2.1 Recent Updates:

The below picture gives an overview of the recent updates:

 2.2 Insights of 9MFY25:

Section 3: Key Risks and Outlook:

Section 4: Stock Recommendation Summary:

4.1 Technical Summary:

 Price Performance:

• Trend Structure and Moving Averages: NVO remains in a downward trend, trading below its 21-day and 50-day moving averages, though recent stabilization around USD 46–47 suggests the stock may be forming a short-term base near its yearly low.
• Momentum Indicators: The RSI near 40 reflects weak but steadying momentum, with subtle higher lows hinting at early signs of improving internal strength despite the lack of a confirmed reversal signal.
• Volume and Technical Outlook: Volume remains moderate, with reduced selling pressure in recent sessions; however, a sustained break above the 21-day and 50-day averages is needed to signal a meaningful recovery from current levels.

4.2 Fundamental Valuation

Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is December 09, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

 Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

 Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.